Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Antibodies, Bispecific × Breast × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 5 Lymphoid 3 Other hematologic neoplasm 2 Tumor-Agnostic 1 Thoracic 1 Plasma cell 1 Head & Neck 1 Gynecologic 1 Gastrointestinal 1 Endocrine 1 Breast 1

Conditions

Triple Negative Breast Neoplasms 1 Breast Neoplasms 1

Interventions

Trastuzumab 724 Paclitaxel 692 Cyclophosphamide 646 Docetaxel 558 Capecitabine 485 Letrozole 432 Carboplatin 396 Fulvestrant 393 Doxorubicin 341 Tamoxifen 305 Anastrozole 276 pembrolizumab 272 exemestane 255 Epirubicin 251 Radiotherapy 237 pertuzumab 232 palbociclib 223 Bevacizumab 222 Gemcitabine 214 Vinorelbine 197 Lapatinib 181 130-nm albumin-bound paclitaxel 172 Magnetic Resonance Spectroscopy 162 Albumin-Bound Paclitaxel 157 eribulin 154 Surveys and Questionnaires 150 Exercise 150 Drug Therapy 139 Taxes 134 Fluorouracil 133

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06404736 2024-05-08

QUEEN-Dream

Fudan University

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡